Events & Insights
Cell therapies that have reached the market are changing lives. The potential to have such an impact drives sponsors to face the complexities and challenges of bringing promising candidates from the lab to the clinic and on to commercialization. The key to completing that journey is developing for commercial success right from the start. Using a design-of-experiment (DoE) approach, adopting a phase-appropriate analytical control strategy, leveraging synergies with an experienced contract development and manufacturing organization, and charting a clear path ensures right-first-time decision-making and optimized products and processes while saving time and cost throughout the development process. Building an effective CMC roadmap not only shows regulators how a process will mature and scale throughout development and commercialization, but also allows anticipation of potential regulatory snags, manufacturing scalability issues, and costly rework before these risks become existential threats.
Components of an Effective CMC Roadmap
An effective CMC roadmap should delineate IND and BLA timelines, including submission milestones, and provide a cost overview. It should also evolve as programs advance from early- to late-phase clinical development and ultimately to commercialization. This evolution is necessary to ensure that all regulatory expectations are met or exceeded, and to map a path from IND filing to BLA submission.
Building a CMC roadmap for a cell therapy candidate begins with defining the target product profile (TPP). Understanding of the therapeutic indication and population, clinical efficacy goals, desired safety profile, expected route of administration and dosage, quality requirements, formulation details, and storage and transportation needs helps ensure selection of critical quality attributes (CQAs) that support the TPP and clinical performance expectations. It also enables determination of the best analytical methods that will robustly link the CQAs and TPP. Early characterization of cell therapy processes using these methods supports more informed decision-making and often helps developers avoid costly delays caused by rework, comparability studies, and other issues.
The identification and minimization of risks that may arise during early clinical development must, in fact, be included in an effective CMC roadmap. The highest risks often relate to manufacturability, raw material and cell source variability, and a lack of early process characterization. Early-stage decisions directly impact the feasibility of scaling to commercial production, including manufacturability assessments early in the CMC roadmap, which help flag potential scaling bottlenecks and other challenges. Evaluation of the availability of key reagents and donor material, and of approaches to ensuring the appropriate chain of identity and chain of custody for patient-derived material, can identify gaps and risks, allowing the development of well-defined supply chain, donor screening, and process development strategies to mitigate and manage them.
Participation in pre-IND meetings with regulators is another important mechanism for minimizing risk. Such meetings provide an opportunity to ensure phase-appropriate alignment with regulatory guidance and to obtain support for the overall CMC strategy. They also provide a forum for getting feedback on intended approaches to assay qualification and raw material sourcing, comparability protocols, data from pilot runs and preliminary stability studies, draft specifications, and the proposed optimization strategy. Phase-based expectations and tangible milestones can also be established, reducing the uncertainty often accompanying complex cell therapy development programs.
Careful, thoughtful process and analytical development, meanwhile, help avoid problems later in development. Clear definitions of both the process and analytical control strategy are essential prior to pursuing cost-effective production of non-GMP material for animal studies. The CMC roadmap should also include fit-for-purpose stability studies (e.g., freeze–thaw effects, in-process holds, and shelf-life). This approach ensures that material produced for preclinical testing is representative of the GMP material that will be used in Phase 1 clinical studies.
Proactive strategies for process and analytical optimization (and more extensive process and method characterization) ensure establishment of robust processes and methods for production of compliant clinical trial material, and ultimately, support for a BLA submission. These activities should be pursued with the initial expected clinical trial needs in mind. Analytics should be built to provide sufficient information at each phase by allowing necessary refinements as programs mature. The CMC roadmap at this stage should also address potential comparability study design and execution, as well as specification assessment and refinement.
As a program advances to later development stages and commercial launch, an effective CMC roadmap addresses facility capabilities and capacities, cost-of-goods assessments, and the establishment of commercialization partnerships. Sterility assurance and contamination control must also be addressed. Alignment on donor screening, testing, traceability, and transport conditions must be assured. For gene-modified cells, vector and/or editing reagent quality, residuals, replication-competent virus testing, insertional mutagenesis risks, vector copy number, on- and off-target editing, and transgene expression kinetics (as well as product-specific test requirements) must all be considered.
Success is dependent on having sufficient expertise in cell therapy process scaling (out and/or up), raw material sourcing, process and analytical development, GMP manufacturing, and regulatory compliance. If built correctly, the CMC roadmap can help cell therapy developers accelerate their programs while ensuring high-quality, future-proof regulatory submissions and minimizing costly surprises.
Development for Clinical and Commercial Success at Kincell Bio
Kincell Bio has the expertise and experience to collaboratively build robust CMC roadmaps that support developers from preclinical through commercialization by reducing risk and expediting IND filing and BLA submission. We ensure that CMC development is conducted in a meaningful way, with each phase of clinical development coupled to appropriate product characterization.
We apply “regulatory design thinking” from the outset, mapping CQAs and designing robust manufacturing processes well in advance of pivotal trials. Our strategy relies on integrating process science, quality systems, and regulatory strategy from the start. We build scalable methods and maintain inspection readiness as therapies advance. This front-loading approach not only expedites the submission review process but also avoids costly facility retrofits to meet commercial demand.
Increasing Efficiency Using a DoE Approach
Kincell Bio uses a DoE approach to increase the efficiency of process and analytical development. Traditional one-factor-at-a-time testing is expensive and time-consuming for highly complex cell therapy processes and often does not provide sufficient data to fully evaluate the influence of variations in raw materials and different process parameters on the TPP.
Understanding the potential impacts of different process parameters, patient/donor variability, and raw material variability (viral vectors, editing materials, etc.) on yield, phenotype, and other attributes, as well as on downstream unit operations, is essential. DoE studies accelerate the generation of this information, which supports the identification of CQAs, the determination of how and when best to measure them, and the interpretation of the data. As such, they serve as a foundational starting point for late-stage process characterization and enable the development of phase-appropriate analytical control strategies that can evolve with and inform decision-making throughout the entire clinical program.
Process evaluations leverage data generated during initial DoE assessments and help further mitigate risks and ensure readiness for IND filing. A series of runs using the optimized parameters identified in the initial DoE studies is performed to further optimize the process and fine-tune performance.
With respect to analytics, Kincell Bio takes a relatively comprehensive approach, which helps enable rapid technology transfer. We leverage both phase-appropriate platform (flow cytometry, polymerase chain reaction, automated cell counting, impedance and flow-based killing assays, secretome assessment, sterility, etc.) and custom-developed and validated methods for in-process testing, tracking, and trending to ensure safety, potency, and consistency. Robust release testing panels with high parameter characterization, including backbone release panels that can be rapidly adapted to meet client-specific assay needs, ensure safety, identity, purity, potency, and dose.
Complex cell-based assays are developed using a DoE approach to accelerate method development and facilitate more efficient use of experimental resources and precious raw materials. As in process development, DoE techniques can lead to significant time savings, cost reductions, and improved decision-making in developing robust analytical techniques.
Emphasizing Characterization
Thorough early-phase suitability assessments minimize late-phase risks. As such, characterization is considered just as important as release testing at Kincell Bio. We encourage clients to focus on developing deep process understanding using actionable data to inform relevant risk assessments, which typically requires investing in characterization assays that interrogate aspects of the product beyond those explicitly required for regulatory compliance. Critical reagent management is also important during all method development activities, as many of these assays require different antibodies and other critical reagents that need to be managed, trended and assessed for stability and performance to ensure assay functioning remains consistent.
Achieving Risk Management with a Stage-Gate Approach
Risk management in cell therapy development is about avoiding setbacks and creating the best possible foundation for success. The CMC roadmaps constructed at Kincell Bio focus on managing risk and assuring quality from the earliest stages. By leveraging stage gates and guiding principles, we help innovators mitigate uncertainties early by proactively addressing risks, optimize processes for scalability, and maintain regulatory compliance, all of which simplify decision-making and support alignment of early development with long-term commercialization goals.
Risks are effectively managed by approaching development as a series of milestones, with mitigation strategies defined as part of the product development lifecycle—both of which require effective planning. Stage gates allow Kincell to evaluate cost, time, and quality tradeoffs, ensuring thoughtful decisions as development progresses. Tools such as well-designed DoEs, phase-appropriate analytical control strategies, and careful evaluations of sequential versus parallel processes streamline early development and ensure smoother transitions through each stage.
Driving Cell Therapy Development Success with Effective CMC Roadmaps
Successful cell therapy development requires anticipating and mitigating challenges before they occur. With a focus on right-first-time performance, Kincell Bio’s flexible, integrated approach provides unique, dynamic support to cell therapy developers. Intentional CMC planning is achieved by working closely with our customers to build effective CMC roadmaps that help them avoid common pitfalls throughout the cell therapy development lifecycle.
Implementation of our CMC roadmaps is achieved by leveraging synergies between Kincell Bio’s and our clients’ teams, using a DoE approach to both process and analytical development to enable variability management. The generated data informs quality attributes, expands process knowledge and understanding, enables effective risk assessments, and provides an efficient strategy for optimizing process and analytical controls. The CMC roadmap also supports phase-appropriate control strategies, ensuring ongoing assessment and encouraging continual dialog with our partners and clients.
Combining process characterization and validation with analytical method validation ensures product quality and process and method robustness. Going beyond the typical level of characterization during early development also enables Kincell Bio to increase both process and method robustness, ensuring that specifications taken into late-stage development are appropriate for the product.
Overall, the CMC roadmaps Kincell Bio builds with its clients not only establish clear paths for the consistent manufacturing of cell therapy candidates that meet safety, identity, quality, purity, and potency standards, but also save time, reduce costs, and help programs stay ahead of risk throughout all development stages.
ABOUT THE AUTHORS
Bruce Thompson, PhD
President and Chief Technology Officer
Bruce Thompson, PhD, is President and Chief Technology Officer at Kincell Bio, bringing more than 28 years of experience in cell and gene therapy development and manufacturing. He was the founding CEO of Kincell, where he built the technical and operations team and launched the company’s CDMO offerings. Previously, he held leadership roles at Resilience, Lyell Immunopharma, and Fred Hutchinson Cancer Research Center, where he led GMP manufacturing for multiple active clinical programs and supported six IND filings. Earlier in his career, Bruce spent nearly a decade at Pfizer in Pharmaceutical Sciences. He holds a B.A. in Biology, an M.S. in Biochemistry from The Ohio State University, and a Ph.D. in Microbiology and Immunology from the University of Louisville.
Roger Herr, PhD
Director, Analytical Development
Roger Herr leads analytical development at Kincell Bio, where he builds phase-appropriate, scalable assay strategies for cell therapy programs and is known for transforming complex biology into reliable data. Before joining Kincell, Roger held analytical leadership positions at influential organizations in the biologics space, including Inceptor Bio and Arranta Bio (now Recipharm Advanced Bio). Roger earned his Ph.D. in Molecular Basis of Disease from the Medical University of Ohio at Toledo and a M.S. in Clinical Laboratory Sciences from Michigan State University.
